Erk5 is a mediator to TGFβ1-induced loss of phenotype and function in human podocytes.

Badshah II, Baines DL, Dockrell ME.

Open source

DOI
10.3389/fphar.2014.00071
Published
2014-04-21
Container
Front Pharmacol
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2014.00071,
  title = {Erk5 is a mediator to TGFβ1-induced loss of phenotype and function in human podocytes.},
  author = {Badshah II and  Baines DL and  Dockrell ME.},
  year = {2014},
  journal = {Front Pharmacol},
  doi = {10.3389/fphar.2014.00071},
  url = {https://doi.org/10.3389/fphar.2014.00071}
}

RIS

TY  - JOUR
TI  - Erk5 is a mediator to TGFβ1-induced loss of phenotype and function in human podocytes.
AU  - Badshah II
AU  -  Baines DL
AU  -  Dockrell ME.
PY  - 2014
JO  - Front Pharmacol
DO  - 10.3389/fphar.2014.00071
UR  - https://doi.org/10.3389/fphar.2014.00071
ER  - 

APA

II, B., DL, B., & ME., D. (2014). Erk5 is a mediator to TGFβ1-induced loss of phenotype and function in human podocytes.. Front Pharmacol. https://doi.org/10.3389/fphar.2014.00071

Source records